BioSpace News Archive

Seasoned Financial Expert to Assist in Transition of Financial Duties

Biotech Showcase is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities.

This presentation included new data from human ex vivo studies demonstrating that GPR174 inhibition results in downregulation of checkpoint and tumor-promoting factors.

Encompass Health (NYSE: EHC) today announced the appointment of Anthony “Tony” Hernandez as chief human resources officer, effective Jan. 6, 2020.

OWC Pharmaceutical Research Corp., represented by its wholly-owned subsidiary, One World Cannabis Ltd. announced that, on December 9, 2019, the United States Patent and Trademark Office issued a Notice of Allowance indicating that OWC Israel’s Patent Application No. 15/629,230 directed to cannabis based extracts and topical formulations for use in skin disorders, is allowed for issuance as a patent.

H1, a New York-based healthcare data-driven solutions provider, today announced continued momentum and record customer growth and expansion of its global healthcare analytics platforms.

AVROBIO (NASDAQ: AVRO) (the “Company”), a leading clinical stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock option to a new employee as an inducement award outside of the Company’s 2018 Stock Option and Incentive Plan, in accordance with NASDAQ Listing Rule 5635(c)(4).

Cyclo Therapeutics, Inc. (OTCQB:CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced its presentation at the WORLDSymposium (“We’re Organizing Research on Lysosomal Diseases”) to be held in Orlando, Florida, between February 10-13, 2020.

etectRx®, Inc. (etectRx), a privately-held digital health company, has announced U.S. Food and Drug Administration (FDA) clearance of its breakthrough patented ingestible event marker, the ID-Cap® System.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the 48-week, Phase 2 ATLAS study of combination and monotherapy investigational treatments for advanced fibrosis (F3-F4) due to NASH